[go: up one dir, main page]

NO20024159D0 - Derivater av kinolin som alfa-2 antagonister - Google Patents

Derivater av kinolin som alfa-2 antagonister

Info

Publication number
NO20024159D0
NO20024159D0 NO20024159A NO20024159A NO20024159D0 NO 20024159 D0 NO20024159 D0 NO 20024159D0 NO 20024159 A NO20024159 A NO 20024159A NO 20024159 A NO20024159 A NO 20024159A NO 20024159 D0 NO20024159 D0 NO 20024159D0
Authority
NO
Norway
Prior art keywords
quinoline
antagonists
alpha
derivatives
Prior art date
Application number
NO20024159A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024159L (no
Inventor
Siegfried Wurster
Mia Enstroem
Juha-Matti Savola
Lisa Hoeglund
Jukka Sallinen
Antti Haapalinna
Andrei Tauber
Anna-Marja Fren
Harri Salo
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of NO20024159D0 publication Critical patent/NO20024159D0/no
Publication of NO20024159L publication Critical patent/NO20024159L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20024159A 2000-03-01 2002-08-30 Derivater av kinolin som alfa-2 antagonister NO20024159L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (fi) 2000-03-01 2000-03-01 Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
PCT/FI2001/000203 WO2001064645A2 (en) 2000-03-01 2001-02-28 Derivatives of quinoline as alpha-2 antagonists

Publications (2)

Publication Number Publication Date
NO20024159D0 true NO20024159D0 (no) 2002-08-30
NO20024159L NO20024159L (no) 2002-08-30

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024159A NO20024159L (no) 2000-03-01 2002-08-30 Derivater av kinolin som alfa-2 antagonister

Country Status (21)

Country Link
EP (1) EP1263733A2 (es)
JP (1) JP2003525274A (es)
KR (1) KR20020089372A (es)
CN (1) CN1468224A (es)
AR (1) AR034249A1 (es)
AU (1) AU2001239331A1 (es)
BR (1) BR0108816A (es)
CA (1) CA2400657A1 (es)
CZ (1) CZ20022880A3 (es)
EE (1) EE200200490A (es)
FI (1) FI20000480A0 (es)
HU (1) HUP0204458A3 (es)
IL (1) IL151093A0 (es)
MX (1) MXPA02008402A (es)
NO (1) NO20024159L (es)
PE (1) PE20011084A1 (es)
PL (1) PL357874A1 (es)
RU (1) RU2002125944A (es)
SK (1) SK12332002A3 (es)
WO (1) WO2001064645A2 (es)
ZA (1) ZA200206956B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361869C2 (ru) * 2002-02-05 2009-07-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые арил- и гетероарилпиперазины
BR0307429A (pt) * 2002-02-05 2004-12-28 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
EA008537B1 (ru) 2002-04-03 2007-06-29 Орион Корпорейшн Полициклические соединения как эффективные антагонисты альфа2-адренорецептора
JP2005521728A (ja) * 2002-04-03 2005-07-21 オリオン コーポレーション ＣＮＳ関連疾患のためのα２−アドレナリン受容体アンタゴニストの使用
EP1499593A4 (en) * 2002-04-30 2006-02-01 Yungjin Pharmacautical Co Ltd QUINOLINE DERIVATIVES INHIBITORS OF CASPASE-3, PREPARATION FOR OBTAINING THEM, AND PHARMACEUTICAL PREPARATIONS COMPRISING SAME
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
US8501739B2 (en) 2005-07-04 2013-08-06 High Point Pharmaceuticals, Llc Medicaments
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
MX2008014921A (es) * 2006-05-22 2008-12-09 Janssen Pharmaceutica Nv Derivados de piracinona sustituidos para uso como un medicamento.
WO2007135111A1 (en) 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
EP2356106A1 (en) 2008-10-07 2011-08-17 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
CN103524413B (zh) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 氢化吖啶衍生物及其应用
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
US10183912B2 (en) 2014-03-31 2019-01-22 MiRx Pharmaceuticals, LLC HDMX inhibitors and their use for cancer treatment
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
CN117999075A (zh) * 2021-09-07 2024-05-07 吉斯莫治疗股份有限公司 包含淀粉样肽与糖胺聚糖相互作用的抑制剂的化合物和药物组合物、治疗方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
WO2001064645A2 (en) 2001-09-07
FI20000480A0 (fi) 2000-03-01
PE20011084A1 (es) 2001-10-25
MXPA02008402A (es) 2003-10-14
KR20020089372A (ko) 2002-11-29
AR034249A1 (es) 2004-02-18
WO2001064645A3 (en) 2001-12-27
NO20024159L (no) 2002-08-30
CZ20022880A3 (cs) 2003-06-18
RU2002125944A (ru) 2004-02-27
SK12332002A3 (sk) 2003-07-01
AU2001239331A1 (en) 2001-09-12
HUP0204458A3 (en) 2004-07-28
IL151093A0 (en) 2003-04-10
HUP0204458A2 (hu) 2003-04-28
BR0108816A (pt) 2002-12-10
PL357874A1 (en) 2004-07-26
EE200200490A (et) 2003-12-15
EP1263733A2 (en) 2002-12-11
CA2400657A1 (en) 2001-09-07
CN1468224A (zh) 2004-01-14
ZA200206956B (en) 2003-12-01
JP2003525274A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
NO20024159L (no) Derivater av kinolin som alfa-2 antagonister
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
NO20022139D0 (no) Kinazolinderivater som VEGF inhibitorer
NO20024387L (no) Karboksylsyrederivater som IP-antagonister
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20030055D0 (no) Colchinolderivater som angiogenese inhibitorer
DK1406628T3 (da) Tetrahydroquinolin-derivater
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
DK1650203T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
NO20015365L (no) Piperidinderivater som er anvendbare som CCR5-antagonister
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
NO20021860L (no) Formulering av substituerte benzimidazoler
DK1464641T3 (da) 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
NO20025542L (no) Kinolonkarboksylsyrederivater
NO20021730D0 (no) Ny formulering av mirtazapin
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
IS6610A (is) Nýjar blöndur alfa-2,4-dísúlfófenýl-N-tert-bútýlnítróns
NO20023785L (no) Vanndispergerbar formulering av paroxetin
ATE367379T1 (de) Quinolin-derivate als antientzündungsmittel
DK1330453T3 (da) Indolylpiperidinderivater som antihistamin- og anti-allergimidler
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application